A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly

New England Journal of Medicine

Volumn 348, Issue 7, 2003, Pages 583-592

  Wing, Lindon M H ^a   Reid, Christopher M ^b   Ryan, Philip ^c   Beilin, Lawrence J ^d   Brown, Mark A ^e   Jennings, Garry L R ^b   Johnston, Colin I ^b   McNeil, John J ^f   Macdonald, Graham J ^g   Marley, John E ^h   Morgan, Trefor O ⁱ   West, Malcolm J ^j  

^a FLINDERS UNIVERSITY   (Australia)

^b BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^c UNIVERSITY OF ADELAIDE   (Australia)

^d UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^e UNIVERSITY OF NEW SOUTH WALES   (Australia)

^f MONASH UNIVERSITY   (Australia)

^g Merck Sharp and Dohme (Australia)   (Australia)

^h UNIVERSITY OF NEWCASTLE   (Australia)

ⁱ UNIVERSITY OF MELBOURNE   (Australia)

^j UNIVERSITY OF QUEENSLAND   (Australia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

AGE DISTRIBUTION; AGED; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; HYPERTENSION; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SEX DIFFERENCE; SEX RATIO; STROKE; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; DIURETICS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERTENSION; MALE; PROSPECTIVE STUDIES; SEX FACTORS;

EID: 0037434556     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMoa021716     Document Type: Article

References (43)

1. Veterans Administration Co-operative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension. II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. JAMA 1970;213:1143-52.
2. The Australian therapeutic trial in mild hypertension: report by the Management Committee. Lancet 1980;1:1261-7.
3. Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principal results. Br Med J (Clin Res Ed) 1985;291:97-104.
4. Idem. Medical Research Council trial of treatment of hypertension in older adults: principal results. BMJ 1992;304:405-12.
5. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991;265:3255-64.
6. Dahlöf B, Lindholm LH, Hansson L, Schersten B, Ekbom T, Wester P-O. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet 1991;338:1281-5.
7. Staessen JA, Fagard R, Thijs L, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 1997;350:757-64.
8. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987;316:1429-35.
9. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fraction and congestive heart failure. N Engl J Med 1991;325:293-302.
10. Rutherford JD, Pfeffer MA, Moye LA, et al. Effects of captopril on ischemic events after myocardial infarction: results of the Survival and Ventricular Enlargement trial. Circulation 1994;90:1731-8.
11. Dahlöf B, Pennert K, Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients: a metaanalysis of 109 treatment studies. Am J Hypertens 1992;5:95-110.
12. Weidmann P, Uehlinger D, Gerber A. Antihypertensive treatment and serum lipoproteins. J Hypertens 1985;3:297-306.
13. Pollare T, Lithell H, Berne C. A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N Engl J Med 1989;321:868-73.
14. Gavras H, Brunner HR, Laragh JH. Renin and aldosterone and the pathogenesis of hypertensive vascular damage. Prog Cardiovasc Dis 1974;17:39-49.
15. Hansson L, Lindholm L, Ekbom T, et al. Randomised trial ofold and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999;354:1751-6.
16. Hansson L, Lindholm LH, Niskanen L, et al. Effect of angiotensin-convertingenzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999;353:611-6.
17. Brown MJ, Palmer CR, Castaigne A, et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000; 356:366-72. [Erratum, Lancet 2000;356:514.]
18. Hansson L, Hedner T, Lund-Johansen P, et al. Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet 2000;356:359-65.
19. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Lancet 2000;356:1955-64.
20. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-53. [Erratum, N Engl J Med 2000;342:748, 1376.]
21. Dahlöf B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Lorsatan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003.
22. Reid CM, Ryan P, Nelson M, et al. General practitioner participation in the second Australian National Blood Pressure Study (ANBP2). Clin Exp Pharmacol Physiol 2001;28:663-7.
23. Reid CM, Ryan P, Wing LMH. The 2nd Australian National Blood Pressure Study (ANBP2). In: Black HR, ed. Clinical trials in hypertension. New York: Marcel Dekker, 2001:587-604.
24. Australian comparative outcome trial of angiotensin-converting enzyme inhibitorand diuretic-based treatment of hypertension in the elderly (ANBP2): objectives and protocol. Clin Exp Pharmacol Physiol 1997;24:188-92.
25. Hansson L, Hedner T, Dahlöf B. Prospective Randomized Open Blinded Endpoint (PROBE) Study: a novel design for intervention trials. Blood Press 1992;1:113-9.
26. British Hypertension Society. Blood pressure measurement. London: British Medical Journal, 1993.
27. Declaration of Helsinki: recommendations guiding physicians in biomedical research involving human subjects. Bull Pan Am Health Organ 1990;24:606-9.
28. Reid CM, Wing LMH, Graham DH. A new paradigm for funding cardiovascularoutcome research in general practice: the Second Australian National Blood Pressure Study. Med J Aust 1998;169:349-50.
29. Wei LJ, Lin DY, Weissfeld L. Regression analysis of multivariate incomplete failure time data by modeling marginal distributions. J Am Stat Assoc 1989;84:1065-73.
30. Li QH, Lagakos WS. Use of the Wei-Lin-Weissfeld method for the analysis of a recurring and a terminating event. Stat Med 1997;16:925-40.
31. Guidelines Subcommittee. 1999 WHO International Society of Hypertension Guidelines for the Management of Hypertension. J Hypertens 1999;17:151-83.
32. Šidák Z. Rectangular confidence regions for the means of multivariate normal distributions. J Am Stat Assoc 1967;62:626-33.
33. Altman D, Andersen PK. Calculating the number needed to treat for trials where the outcome is time to an event. BMJ 1999;319:1492-5.
34. UK Prospective Diabetes Study Group. Efficacy ofatenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998;317:713-20.
35. Major outcomes in high-risk hypertensive patients randomized to angiotensinconverting enzyme inhibitor or calcium channel blocker vs. diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981-97.
36. Davis BR, Cutler JA, Gordon DJ, et al. Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Ana J Hypertens 1995;9:342-60.
37. World Health Organization-International Society of Hypertension Blood Pressure Lowering Treatment Trialists Collaboration. Protocol for prospective collaborative overviews of major randomized trials of blood-pressure-lowering treatments. J Hypertens 1998;16:127-37.
38. Australian Institute of Health and Welfare, Heart Foundation of Australia. Heart, stroke and vascular diseases - Australian facts 2001. Cardiovascular disease series no. 14. Canberra, Australia: National Heart Foundation of Australia, 2001. (AIHW cat. no. CVD 13.)
39. Hlubocka Z, Umnerova V, Heller S, et al. Circulating intercellular cell adhesion molecule-1, endothelin-1 and von Willebrand factor - markers of endothelial dysfunction in uncomplicated essential hypertension: the effect oftreatment with ACE inhibitors. J Hum Hypertens 2002;16:557-62.
40. The SOLVD Investigators. Effect ofenalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992;327:685-91. [Erratum, N Engl J Med 1992;327:1768.]
41. Marre M, Chatellier G, Leblanc H, Guyene TT, Menard J, Passa P. Prevention of diabetic nephropathy with enalapril in normotensive diabetics with microalbuminuria. BMJ 1988;297:1092-5.
42. Mathiesen ER, Hommel E, Giese J, Parving H-H. Efficacy of captopril in postponing nephropathy in normotensive insulin dependent diabetic patients with microalbuminuria. BMJ 1991;303:81-7.
43. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-convertingenzyme inhibition on diabetic nephropathy. N Engl J Med 1993;329:1456-62. [Erratum N Engl J Med 1993;330:152.]